A case-control study on effects of irbesartan and amlodipino on insulin sensitivity in obese hypertensive pa-tients

VernacularTitle:厄贝沙坦与氨氯地平对肥胖高血压患者胰岛素敏感性影响的对照研究
Author: Shuwen YANG ; Jing FU ; Yan ZHANG
Publication Type:Journal Article
Keywords: Hypertension; Obesity; Irbesartan; Amlodipine
From: Clinical Medicine of China 2009;25(10):1055-1057
CountryChina
Language:Chinese
Abstract: Objective To observe the effects of irbesartan and amlodipine on insulin sensitivity in obese hypertensive patients. Methods 157 moderate hypertensive patients were divided into two greups,which received irbesartan or amlodipine for 16 weeks. The changes of blood pressure,heart rate and weight were observed. Insulin re-sistance was computed using the homeostasis model assessment (HOMA-IR). Results There was no difference in antihypertensive efficacy between the two groups(P>0.05). After 16 weeks of treatment ,the insulin resistance index decreased by 8.7±2.4 vs 6.1±2.6 (P<0.01) and body mass index decreased(28.1±3.8) kg/m2 vs (27.2± 3.2 ) kg/m2 (P<0.05 ) and mean heart rate raised by (73.1 ±10.0 ) kg/m2 vs ( 79.1±11.4) kg/m2 ( P < 0.01 ) in irbesartan group while no such changes were found in amlodipine treated group. Conclusions In obese hypertensive patients,irbsartan and amlodipine exert similar antihypertensive effect, but irbesartan may help to improve some obe-sity-related metabolize disorder,so the obese hypertensive patients may benefit more from irbsartan than from amlo-dipine.